Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

Title:Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases

Volume: 23 Issue: 41

Author(s): Chongshan Liao, Chengfei Zhang and Yanqi Yang*

Affiliation:

• Orthodontics, Faculty of Dentistry, The University of Hong Kong, Sai Ying Pun, Hong Kong SAR,China

Keywords: IL-17, IL-17 receptor, bone loss, osteoclastogensis, RANKL, osteoclasts.

Abstract: Bone remodelling is a strictly regulated dynamic process between bone resorption and bone formation. Many factors are involved in the process and affect the dynamic balance. Inflammation-mediated bone loss is a major feature of various bone diseases, including periodontitis, rheumatoid arthritis (RA) and spondyloarthritis (SpA). Interleukin-17 (IL-17) plays an important role in inflammatory bone disease and could be an attractive therapeutic target. This review focuses on the osteoclastic effects of IL-17 in different cell types and summarizes the current knowledge of IL-17 signalling pathways. Typical IL-17–mediated bone destruction disorders are examined. The review also provides an overview of possible strategies for therapeutic intervention for inflammatory loss of bone targeting IL-17.

Cite this article as:

Liao Chongshan , Zhang Chengfei and Yang Yanqi *, Pivotal Roles of Interleukin-17 as the Epicenter of Bone Loss Diseases, Current Pharmaceutical Design 2017; 23 (41) . https://dx.doi.org/10.2174/1381612823666170519120040